Turbine launched Transfyr, a new product that builds on data showing reproducibility matters more than raw data volume.

Turbine is virtualizing biological experiments with AI to accelerate drug discovery and enhance clinical translatability. We’ve spent the last decade building virtual disease models designed to ultimately become second only to the patient in predicting drug response. By simulating how cells and tissues behave under treatment, Turbine helps pharma identify the right therapeutic ideas smarter and faster, cutting years of dead-end research and reducing Phase II failure caused by poor efficacy. Scientists can now run billions of virtual experiments to uncover risk, design smarter trials, and scale decisions across entire pipelines. Validated through partnerships with Bayer, AstraZeneca and others, Turbine’s platform has supported nearly 30 research programs. Backed by Accel, MSD Global Health Innovation Fund, we’re putting predictive simulations in the hands of every scientist.